Publications by authors named "K Folkers"
The U.S. and Japan have preapproval access systems for patients who have exhausted approved treatment options.
View Article and Find Full Text PDFObjective: To evaluate the availability of information regarding patient access to investigational treatments through clinical trials and non-trial pre-approval access pathways from a sample of patient advocacy organization (PAO) websites in the United States.
Results: We systematically analyzed the content of 118 randomly selected PAO websites to assess whether they contained information on clinical trials and non-trial pathways-e.g.
Article Synopsis
- * Supporters of the right-to-try movement argue that patients should have access to experimental therapies, while opponents raise concerns about medical paternalism and the government's role in overseeing such access.
- * The outcomes of the right-to-try movement could either lead to no significant increase in access to investigational drugs or allow companies to exploit the law for financial gain without proper oversight on costs.
Background: U.S. physicians may treat a patient with an investigational drug outside of a clinical trial by using the expanded access (EA) pathway or the recently created federal right to try (RTT) pathway.
View Article and Find Full Text PDF